2012-12-27 |
2012-12-24 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
17.500
-31.7%
22,53
394.301 USD
|
17.500
-31.7%
|
22,53
|
394.301 USD
|
|
2012-12-17 |
2012-12-13 |
V
Verkauf
|
BROOKE PAUL A
Nicht geschäftsführender Verwaltungsratsmitglied
|
60.000
-36.5%
23,87
1.431.954 USD
|
60.000
-36.5%
|
23,87
|
1.431.954 USD
|
|
2012-12-12 |
2012-12-10 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
14.999
-28.5%
24,07
360.984 USD
|
14.999
-28.5%
|
24,07
|
360.984 USD
|
|
2012-12-12 |
2012-12-10 |
V
Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
50.000
-57.0%
24,07
1.203.360 USD
|
50.000
-57.0%
|
24,07
|
1.203.360 USD
|
|
2012-12-12 |
2012-12-10 |
V
Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
10.000
-21.0%
24,07
240.672 USD
|
10.000
-21.0%
|
24,07
|
240.672 USD
|
|
2012-12-05 |
2012-12-03 |
V
Verkauf
|
Wolf John Peter III
VP, General Counsel
Führungsperson
|
18.000
-100.0%
24,85
447.257 USD
|
18.000
-100.0%
|
24,85
|
447.257 USD
|
|
2012-12-05 |
2012-12-03 |
K
Kauf
|
DOUGHERTY MICHAEL R
Nicht geschäftsführender Verwaltungsratsmitglied
|
2.500
+55.6%
25,07
62.675 USD
|
2.500
+55.6%
|
25,07
|
62.675 USD
|
|
2012-12-05 |
2012-12-03 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
-18.3%
24,80
248.000 USD
|
10.000
-18.3%
|
24,80
|
248.000 USD
|
|
2012-12-04 |
2012-11-30 |
V
Verkauf
|
GLASER ROBERT
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
-19.5%
24,78
247.795 USD
|
10.000
-19.5%
|
24,78
|
247.795 USD
|
|
2012-12-04 |
2012-11-30 |
V
Verkauf
|
GLASER ROBERT
Nicht geschäftsführender Verwaltungsratsmitglied
|
20.000
-32.6%
24,78
495.590 USD
|
20.000
-32.6%
|
24,78
|
495.590 USD
|
|
2012-11-30 |
2012-11-28 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
15.000
-21.6%
24,22
363.326 USD
|
15.000
-21.6%
|
24,22
|
363.326 USD
|
|
2012-11-30 |
2012-11-28 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
2.500
-4.4%
24,22
60.554 USD
|
2.500
-4.4%
|
24,22
|
60.554 USD
|
|
2012-11-15 |
2012-11-13 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
12.500
-18.7%
25,01
312.585 USD
|
12.500
-18.7%
|
25,01
|
312.585 USD
|
|
2012-11-15 |
2012-11-13 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
-15.5%
24,84
248.426 USD
|
10.000
-15.5%
|
24,84
|
248.426 USD
|
|
2012-11-13 |
2012-11-08 |
V
Verkauf
|
MILANO VINCENT
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
41.418
-30.5%
24,54
1.016.522 USD
|
41.418
-30.5%
|
24,54
|
1.016.522 USD
|
|
2012-11-13 |
2012-11-08 |
V
Verkauf
|
MILANO VINCENT
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
42.000
-30.8%
24,54
1.030.806 USD
|
42.000
-30.8%
|
24,54
|
1.030.806 USD
|
|
2012-11-05 |
2012-11-02 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
-15.5%
25,37
253.703 USD
|
10.000
-15.5%
|
25,37
|
253.703 USD
|
|
2012-06-13 |
2012-06-11 |
V
Verkauf
|
CLAYPOOL WILLIAM D MD
Nicht geschäftsführender Verwaltungsratsmitglied
|
10.000
-13.4%
20,04
200.430 USD
|
10.000
-13.4%
|
20,04
|
200.430 USD
|
|
2012-03-27 |
2012-03-23 |
GV
Geplanter Verkauf
|
Pietrusko Robert
VP, Regulatory & Quality
Führungsperson
|
20.000
-82.9%
30,00
600.000 USD
|
20.000
-82.9%
|
30,00
|
600.000 USD
|
|
2012-03-12 |
2012-03-09 |
V
Verkauf
|
Morris Richard Steven
Chief Accounting Officer
Führungsperson
|
1.300
-51.1%
29,71
38.618 USD
|
1.300
-51.1%
|
29,71
|
38.618 USD
|
|
2012-03-12 |
2012-03-09 |
V
Verkauf
|
Fletcher Robert C.
V.P., Business Development
Führungsperson
|
32.000
-99.3%
29,65
948.954 USD
|
32.000
-99.3%
|
29,65
|
948.954 USD
|
|
2012-03-07 |
2012-03-05 |
V
Verkauf
|
Morris Richard Steven
Chief Accounting Officer
Führungsperson
|
5.300
-81.0%
33,01
174.953 USD
|
5.300
-81.0%
|
33,01
|
174.953 USD
|
|
2012-03-07 |
2012-03-05 |
V
Verkauf
|
DOYLE THOMAS F
VP Strategic Initiatives
Führungsperson
|
210.000
-80.0%
32,48
6.820.212 USD
|
210.000
-80.0%
|
32,48
|
6.820.212 USD
|
|
2012-03-06 |
2012-03-01 |
V
Verkauf
|
SOLAND DANIEL B
VP, Chief Operating Officer
Führungsperson
|
30.000
-41.2%
32,99
989.700 USD
|
30.000
-41.2%
|
32,99
|
989.700 USD
|
|
2012-03-05 |
2012-03-01 |
V
Verkauf
|
Rowland Charles A Jr
VP, Chief Financial Officer
Führungsperson
|
12.750
-42.7%
32,11
409.434 USD
|
12.750
-42.7%
|
32,11
|
409.434 USD
|
|
2012-03-05 |
2012-03-01 |
V
Verkauf
|
Rowland Charles A Jr
VP, Chief Financial Officer
Führungsperson
|
70.000
-70.1%
32,12
2.248.197 USD
|
70.000
-70.1%
|
32,12
|
2.248.197 USD
|
|
2011-12-16 |
2011-12-14 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
50.566
+2.6%
27,29
1.379.860 USD
|
50.566
+2.6%
|
27,29
|
1.379.860 USD
|
|
2011-12-16 |
2011-12-14 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
291.706
+3.1%
27,29
7.960.161 USD
|
291.706
+3.1%
|
27,29
|
7.960.161 USD
|
|
2011-12-16 |
2011-12-14 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
7.828
+2.6%
27,29
213.613 USD
|
7.828
+2.6%
|
27,29
|
213.613 USD
|
|
2011-12-15 |
2011-12-14 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
25.000
-56.3%
25,17
629.250 USD
|
25.000
-56.3%
|
25,17
|
629.250 USD
|
|
2011-12-15 |
2011-12-14 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
25.000
-56.3%
25,50
637.500 USD
|
25.000
-56.3%
|
25,50
|
637.500 USD
|
|
2011-12-14 |
2011-12-13 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
22.330
-53.5%
23,50
524.755 USD
|
22.330
-53.5%
|
23,50
|
524.755 USD
|
|
2011-12-14 |
2011-12-12 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
17.670
-47.6%
23,50
415.317 USD
|
17.670
-47.6%
|
23,50
|
415.317 USD
|
|
2011-12-05 |
2011-12-01 |
V
Verkauf
|
DOYLE THOMAS F
VP Strategic Initiatives
Führungsperson
|
10.000
-16.0%
23,82
238.159 USD
|
10.000
-16.0%
|
23,82
|
238.159 USD
|
|
2011-12-01 |
2011-11-30 |
GV
Geplanter Verkauf
|
Pietrusko Robert
VP, Regulatory & Quality
Führungsperson
|
20.000
-83.6%
24,00
480.000 USD
|
20.000
-83.6%
|
24,00
|
480.000 USD
|
|
2011-11-29 |
2011-11-28 |
GV
Geplanter Verkauf
|
Pietrusko Robert
VP, Regulatory & Quality
Führungsperson
|
19.000
-82.9%
23,00
437.000 USD
|
19.000
-82.9%
|
23,00
|
437.000 USD
|
|
2011-11-29 |
2011-11-28 |
V
Verkauf
|
GLASER ROBERT
Nicht geschäftsführender Verwaltungsratsmitglied
|
5.000
-11.9%
23,00
115.000 USD
|
5.000
-11.9%
|
23,00
|
115.000 USD
|
|
2011-11-28 |
2011-11-23 |
GV
Geplanter Verkauf
|
Pietrusko Robert
VP, Regulatory & Quality
Führungsperson
|
1.000
-25.6%
23,00
23.000 USD
|
1.000
-25.6%
|
23,00
|
23.000 USD
|
|
2011-11-23 |
2011-11-21 |
GV
Geplanter Verkauf
|
MILANO VINCENT
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
41.691
-35.4%
22,53
939.127 USD
|
41.691
-35.4%
|
22,53
|
939.127 USD
|
|
2011-11-23 |
2011-11-21 |
GV
Geplanter Verkauf
|
MILANO VINCENT
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
19.996
-20.8%
22,53
450.428 USD
|
19.996
-20.8%
|
22,53
|
450.428 USD
|
|
2011-11-23 |
2011-11-21 |
GV
Geplanter Verkauf
|
MILANO VINCENT
President and CEO
Geschäftsführender Verwaltungsratsmitglied
|
15.000
-16.4%
22,53
337.889 USD
|
15.000
-16.4%
|
22,53
|
337.889 USD
|
|
2011-11-17 |
2011-11-16 |
V
Verkauf
|
Morris Richard Steven
Chief Accounting Officer
Führungsperson
|
2.000
-63.2%
22,59
45.181 USD
|
2.000
-63.2%
|
22,59
|
45.181 USD
|
|
2011-11-15 |
2011-11-14 |
GV
Geplanter Verkauf
|
Pietrusko Robert
VP, Regulatory & Quality
Führungsperson
|
20.000
-83.6%
22,00
440.000 USD
|
20.000
-83.6%
|
22,00
|
440.000 USD
|
|
2011-11-09 |
2011-11-07 |
V
Verkauf
|
Wolf John Peter III
VP, General Counsel
Führungsperson
|
12.250
-100.0%
21,08
258.194 USD
|
12.250
-100.0%
|
21,08
|
258.194 USD
|
|
2011-11-08 |
2011-11-07 |
V
Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
200
-1.0%
21,01
4.202 USD
|
200
-1.0%
|
21,01
|
4.202 USD
|
|
2011-11-08 |
2011-11-07 |
V
Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
19.800
-50.2%
21,00
415.800 USD
|
19.800
-50.2%
|
21,00
|
415.800 USD
|
|
2011-11-02 |
2011-11-01 |
GV
Geplanter Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
24.121
-55.4%
20,05
483.641 USD
|
24.121
-55.4%
|
20,05
|
483.641 USD
|
|
2011-11-02 |
2011-10-31 |
V
Verkauf
|
Broom Colin MD
VP & Chief Scientific Officer
Führungsperson
|
20.495
-51.3%
20,42
418.555 USD
|
20.495
-51.3%
|
20,42
|
418.555 USD
|
|
2011-10-06 |
2011-10-05 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
145.763
+1.6%
18,18
2.650.423 USD
|
145.763
+1.6%
|
18,18
|
2.650.423 USD
|
|
2011-10-06 |
2011-10-05 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
16.278
+0.9%
18,18
295.985 USD
|
16.278
+0.9%
|
18,18
|
295.985 USD
|
|
2011-10-06 |
2011-10-05 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
6.017
+2.1%
18,18
109.408 USD
|
6.017
+2.1%
|
18,18
|
109.408 USD
|
|
2011-10-06 |
2011-10-04 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
45.584
+0.5%
17,48
796.644 USD
|
45.584
+0.5%
|
17,48
|
796.644 USD
|
|
2011-10-06 |
2011-10-04 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
2.511
+0.1%
17,48
43.883 USD
|
2.511
+0.1%
|
17,48
|
43.883 USD
|
|
2011-10-06 |
2011-10-04 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
1.905
+0.7%
17,48
33.293 USD
|
1.905
+0.7%
|
17,48
|
33.293 USD
|
|
2011-10-03 |
2011-10-03 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
445.574
+5.0%
17,71
7.890.269 USD
|
445.574
+5.0%
|
17,71
|
7.890.269 USD
|
|
2011-10-03 |
2011-10-03 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
70.629
+0.8%
17,62
1.244.589 USD
|
70.629
+0.8%
|
17,62
|
1.244.589 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
88.657
+1.0%
18,08
1.602.892 USD
|
88.657
+1.0%
|
18,08
|
1.602.892 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
43.321
+0.5%
18,19
788.122 USD
|
43.321
+0.5%
|
18,19
|
788.122 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
13.576
+0.7%
18,08
245.450 USD
|
13.576
+0.7%
|
18,08
|
245.450 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
6.634
+0.4%
18,19
120.690 USD
|
6.634
+0.4%
|
18,19
|
120.690 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
3.367
+1.2%
18,08
60.874 USD
|
3.367
+1.2%
|
18,08
|
60.874 USD
|
|
2011-10-03 |
2011-09-30 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
1.645
+0.6%
18,19
29.927 USD
|
1.645
+0.6%
|
18,19
|
29.927 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
159.945
+1.9%
18,00
2.878.882 USD
|
159.945
+1.9%
|
18,00
|
2.878.882 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
21.117
+1.1%
18,00
380.089 USD
|
21.117
+1.1%
|
18,00
|
380.089 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
6.084
+2.2%
18,00
109.507 USD
|
6.084
+2.2%
|
18,00
|
109.507 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
89.970
+1.1%
17,97
1.616.392 USD
|
89.970
+1.1%
|
17,97
|
1.616.392 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
11.878
+0.6%
17,97
213.399 USD
|
11.878
+0.6%
|
17,97
|
213.399 USD
|
|
2011-10-03 |
2011-09-29 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
3.423
+1.3%
17,97
61.497 USD
|
3.423
+1.3%
|
17,97
|
61.497 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
4.697
+0.3%
18,13
85.155 USD
|
4.697
+0.3%
|
18,13
|
85.155 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
22.084
+1.2%
18,13
400.295 USD
|
22.084
+1.2%
|
18,13
|
400.295 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
1.103
+0.4%
18,13
19.997 USD
|
1.103
+0.4%
|
18,13
|
19.997 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
14159 capital (GP), LLC
Large shareholder
|
5.184
+1.9%
18,13
93.965 USD
|
5.184
+1.9%
|
18,13
|
93.965 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
28.000
+0.3%
18,13
507.632 USD
|
28.000
+0.3%
|
18,13
|
507.632 USD
|
|
2011-09-26 |
2011-09-26 |
K
Kauf
|
Baker Brothers Life Sciences Capital (GP), LLC
Large shareholder
|
131.641
+1.6%
18,13
2.386.125 USD
|
131.641
+1.6%
|
18,13
|
2.386.125 USD
|
|
2011-09-26 |
2011-09-23 |
K
Kauf
|
Baker Biotech Capital (GP), LLC
Large shareholder
|
8.828
+0.5%
17,78
156.988 USD
|
8.828
+0.5%
|
17,78
|
156.988 USD
|
|